Teresa DeHaemer, our Senior Director of Business Strategy shares just a small part of her experience at hashtag#RAD2025 – The Revolutionizing Atopic Dermatitis conference in Nashville, which took place June 6th and 7th. Joined by Tyler White, our Senior Director of Business Development, Thalocan Research Innovations expresses our sincere thanks for all the insight, presentations,…
DetailsTeresa DeHaemer, our Senior Director of Business Strategy shares just a small part of her experience at hashtag#RAD2025 – The Revolutionizing Atopic Dermatitis conference in Nashville, which took place June 6th and 7th. Joined by Tyler White, our Senior Director of Business Development, Thalocan Research Innovations expresses our sincere thanks for all the insight, presentations,…
DetailsIn recognition of Hidradenitis Suppurativa Awareness week, Thalocan Research Innovations is proud to present our full conversation with Portia Combow, who graciously shares her story about living with HS for nearly twenty years. The generosity of people like Portia not only recognizes all of those who cope with this disease, but serves to inform many…
DetailsThe third installment in our series, Conversations with Portia Combow: After being incorrectly diagnosed, first with a staph infection and then with folliculitis – Portia discusses her experience and the treatment options she pursued prior to getting correctly diagnosed with Hidradenitis Suppurativa. Watch the full webinar/conversation at www.thalocan.com/webinars/.
“How long did it take to get your diagnosis?” is the next topic in our series, Living with HS – conversations with Portia Combow. As Thalocan continues to work to improve the process of disease assessment in clinical research, we are grateful to Portia as she shares her unique and first-hand experience with Hidradenitis Suppurativa.…
DetailsMeet Portia Combow, who has battled Hidradenitis Suppurativa (HS) for nearly two decades. Portia has been generous enough to share her experiences around the stigma, her long journey to diagnosis, as well as her own discovery of disease management strategies. At Thalocan we work to improve the process of disease assessment in clinical research, the patient experience informs all…
DetailsTo effectively address challenges in clinical trial endpoint management within the immuno-dermatology therapeutic area, a strong team is essential. We are proud to introduce the talented and driven individuals who make up Thalocan Research Innovations. Their expertise and dedication help our customers capture meaningful data to identify treatments that improve patients’ quality of life.
Validating new clinical scales is essential for ensuring data quality and consistent rater assessments. However, the process is often costly, complex, and too critical to leave to chance. Sponsors and research organizations need a reliable Consensus process. Scale development projects are too often abandoned due to timeline and budget constraints. To solve this, Thalocan has…
DetailsAccelerating Scale Validation with TAVOS: A Game Changer for Disease Assessment Rater scales have become the standard for measuring endpoints in dermatology clinical research. These instruments are now essential tools for evaluating efficacy in inflammatory skin disease trials. Yet, the process of developing and validating scales remains anything but standard. It is labor-intensive, costly, and…
DetailsWe work hard to be true partners to our clients and collaborators by making their problems our problems. We’re proud of the impact we’ve made and even more honored when our partners share their experiences. Here are a few generous people who took the time to share their experiences with us. We’re grateful for the trust, collaboration,…
Details
